A coating for a medical device is described. The coating comprises: a surface layer; and optionally a base layer; wherein the surface layer comprises a polymer chain attached to an anti-clotting group, wherein the anti-clotting group is selected from a sulfonic acid group, a sulfonamide group, a sulfamic acid group, a hydrogen sulfate group and a conjugate base thereof. Also described is a medical device comprising the coating, and uses and methods involving the coating and the medical device.

The present disclosure provides a technique capable of ensuring good visibility when introducing an embolic agent and reducing the visibility after introduction. Provided is an embolic agent kit. The embolic agent kit includes: a catheter having an inner cavity; a reaction product of an ethylenically unsaturated monomer and a crosslinking agent, which is filled in the inner cavity; and a priming solution containing a visualization agent and configured to prime an inside of the catheter.

The present disclosure provides a technique capable of ensuring good visibility when introducing an embolic agent and reducing the visibility after introduction. Provided is an embolic agent kit. The embolic agent kit includes: a catheter having an inner cavity; a reaction product of an ethylenically unsaturated monomer and a crosslinking agent, which is filled in the inner cavity; and a priming solution containing a visualization agent and configured to prime an inside of the catheter.

Novel, lubricious coatings for medical devices are disclosed. The coatings provide improved lubricity and durability and are readily applied in coating processes a low temperatures that do not deform the device. The present invention is also directed to a novel platinum catalyst for use in such coatings. The catalyst provides for rapid curing, while inhibiting cross-linking at ambient temperatures, thereby improving the production pot life of the coatings.

Novel, lubricious coatings for medical devices are disclosed. The coatings provide improved lubricity and durability and are readily applied in coating processes a low temperatures that do not deform the device. The present invention is also directed to a novel platinum catalyst for use in such coatings. The catalyst provides for rapid curing, while inhibiting cross-linking at ambient temperatures, thereby improving the production pot life of the coatings.

A functionally gradient material for guided periodontal hard and soft tissue regeneration includes a 3D printed scaffold layer and an electrospun fibrous membrane layer. The content of hydroxyapatite in the 3D printed scaffold layer is higher than the content of hydroxyapatite in the electrospun fibrous membrane layer. The pore size of the 3D printed scaffold layer is larger than the pore size of the electrospun fibrous membrane layer. The pore size of the 3D printed scaffold layer is 100-1000 μm, and the fiber diameter of the electrospun fibrous membrane layer is 300-5000 nm. The electrospun fibrous membrane layer is in a random distribution or an oriented arrangement or has a mesh structure. The thickness of the electrospun fibrous membrane layer is 0.08-1 mm.

Described herein is a method of coating a prosthetic device, such as an ocular prosthetic device, the method comprising nanoelectrospraying droplets comprising an active ingredient and/or a carrier species onto a surface of the prosthetic device in a predetermined pattern, the nanoelectrospraying involving controlling the flow rate of the droplets from a nozzle of the nanoelectrospraying equipment by controlling the voltage between the nozzle and the ocular prosthetic device. Also described herein are ocular prosthetic device formable according to the method.

A cardiovascular fibrous implant for rebuilding elastin and the use of such an implant, wherein the implant is comprised of fibers forming a network, and wherein the fibers comprised in said network have a fiber diameter of 150 μm or less.

Disclosed is use of amlexanox or a salt thereof or a solvate thereof in preparation of a drug having an inhibitory action on the smooth muscle cells, in particular a drug for preventing and treating vascular restenosis. Further disclosed is a medical device, particularly a drug stent, the surface of which is distributed with amlexanox or the salt thereof or the pharmaceutical composition thereof. Amlexanox has an activity in inhibition of the proliferation of smooth muscle cells, has a low inhibitory property of the endothelial cell growth, is particularly suitable for applying on a medical device to prevent the incidence of vascular restenosis, while not delaying the repair of endothelium.

Disclosed is use of amlexanox or a salt thereof or a solvate thereof in preparation of a drug having an inhibitory action on the smooth muscle cells, in particular a drug for preventing and treating vascular restenosis. Further disclosed is a medical device, particularly a drug stent, the surface of which is distributed with amlexanox or the salt thereof or the pharmaceutical composition thereof. Amlexanox has an activity in inhibition of the proliferation of smooth muscle cells, has a low inhibitory property of the endothelial cell growth, is particularly suitable for applying on a medical device to prevent the incidence of vascular restenosis, while not delaying the repair of endothelium.